The company, which is only three years removed from one of biotech’s most lucrative IPOs, will cut jobs for a third time and ...

For a small rare disease company with a treatment in the clinic, the toughest challenge isn’t necessarily the science. Often, ...

A medicine built around a more precise form of CRISPR gene editing appeared to work as designed in its first clinical trial ...